LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
General Counsel
General Counsel
Liquidia Corp (LQDA)Equibles does not estimate personal net worth.
Get an email with a short summary when Liquidia Corp publishes a filing, an earnings call transcript or a press release.
Get LQDA alertsRusty Schundler is recorded as General Counsel at Liquidia Corp (LQDA). Rusty Schundler has spoken on 10 earnings calls across 1 company, most recently for Liquidia Corp on November 10, 2026. Liquidia Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Liquidia Corp includes Damian deGoa (CEO and Board Member), Joanna Horobin (CEO), Paul B. Manning (CEO and Board Member) and 7 others.
“As to the legal aspects of moving forward with L606 in PHLD, you know, I think the important thing to remember when you're looking at the 327 patent is it's very much drafted with an eye towards how the Tyveso nebulizer works.”
“So, that's the two questions you asked me. First is the range of outcomes. No change there. You know, it's the same things we've been talking about for, you know, over a year now.”
“I'd like to group the recent litigation and regulatory activity into two buckets. First, those items on the critical path to YUTREPIA’s approval. Second, the recent attempts by United Therapeutics to assert new legal theories to block approval of YUTREPIA.”
“The '061 refers to the patent application that received a notice of allowance back in late June, which we announced in an 8-K. As of today, that patent has not issued, and we have not received a notice of issuance yet.”
“As a reminder, Liquidia has been party to two separate appeal proceedings at the Federal Circuit that are relevant to the launch of YUTREPIA.”
LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
General Counsel